← Back to patent-cliff list
CAS 1370351-45-3
4,4'-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2,4-diyl)dimorpholine
Codes: BUPA-010
Application context (from source-drug indications)
Head and neck squamous cell carcinomaBuparlisibSolid tumourBuparlisib鼻咽肿瘤Buparlisib喉肿瘤Buparlisib口咽肿瘤BuparlisibSquamous cell carcinomaBuparlisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Buparlisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine→5-bromo-4-(trifluoromethyl)pyridin-2-amine→4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)→4,4'-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2,4-diyl)dimorpholine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.